Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 14, 2020 13:34 UTC |
Petersen GregDirector
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001209191-20-009471 · doc4.xml · derivative · entry 1 Petersen Greg · CIK 0001406815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: The options vest over two years as follows: 50% of the shares vest on February 14, 2021 and 1/24th of the shares vest each monthly anniversary thereafter. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:51 UTC |
Sims Andrew John Hugh MacIntyreChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-20-008129 · doc4.xml · derivative · entry 1 Sims Andrew John Hugh MacIntyre · CIK 0001802687 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The options vest over four years as follows: 25% of the shares vest on February 6, 2021 and 1/48th of the shares vest each monthly anniversary thereafter. Read SEC document |
| January 09, 2020 Filed Jan 23, 2020 00:21 UTC |
van Es-Johansson AnDirector
|
GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001209191-20-004536 · doc4.xml · derivative · entry 1 van Es-Johansson An · CIK 0001795902 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The option vests over two years as follows: 50% of the shares vest on January 1, 2021 and 1/24th of the shares vest each monthly anniversary thereafter. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:33 UTC |
Hawkins Richard JDirector
|
OtherWarrants (Right to Buy) · Derivative | 10,500 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044208 · doc4.xml · derivative · entry 3 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2021-01-25 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:33 UTC |
Hawkins Richard JDirector
|
OtherSeries C Preferred Stock · Derivative | 10 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044208 · doc4.xml · derivative · entry 2 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Underlying: Common Stock · 12,522 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series C Preferred Stock has no expiration date. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:33 UTC |
Hawkins Richard JDirector
|
OtherSubscription Rights (Right to Buy) · Derivative | 10 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-044208 · doc4.xml · derivative · entry 1 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: See Footnote · Not disclosed shares Expires 2018-07-20 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:32 UTC |
HEDRICK MARC HPresident and CEO
|
OtherWarrants (Right to Buy) · Derivative | 36,750 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044207 · doc4.xml · derivative · entry 3 HEDRICK MARC H · CIK 0001203672 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,750 Underlying: Common Stock · 36,750 shares Expires 2021-01-25 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:32 UTC |
HEDRICK MARC HPresident and CEO
|
OtherSeries C Preferred Stock · Derivative | 35 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044207 · doc4.xml · derivative · entry 2 HEDRICK MARC H · CIK 0001203672 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Underlying: Common Stock · 43,827 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series C Preferred Stock has no expiration date. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:32 UTC |
HEDRICK MARC HPresident and CEO
|
OtherSubscription Rights (Right to Buy) · Derivative | 35 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-044207 · doc4.xml · derivative · entry 1 HEDRICK MARC H · CIK 0001203672 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: See Footnote · Not disclosed shares Expires 2018-07-20 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:31 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherWarrants (Right to Buy) · Derivative | 1,050 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044206 · doc4.xml · derivative · entry 3 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Underlying: Common Stock · 1,050 shares Expires 2021-01-25 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:31 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherSeries C Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0001209191-18-044206 · doc4.xml · derivative · entry 2 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 1,253 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series C Preferred Stock has no expiration date. Read SEC document |
| July 25, 2018 Filed Jul 27, 2018 20:31 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-044206 · doc4.xml · derivative · entry 1 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: See Footnote · Not disclosed shares Expires 2018-07-20 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 21:05 UTC |
PostFinance AG10% owner
|
SaleCommon Stock | 473,831 | $0.34 | $161,007.77 |
DisclosureSEC source: 0000899243-18-004175 · doc4.xml · nonDerivative · entry 1 PostFinance AG · CIK 0001727276 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,543,086 Read SEC document |
| February 13, 2018 Filed Feb 14, 2018 21:19 UTC |
PostFinance AG10% owner
|
SaleCommon Stock | 101,710 | $0.31 | $31,652.15 |
DisclosureSEC source: 0000899243-18-003865 · doc4.xml · nonDerivative · entry 2 PostFinance AG · CIK 0001727276 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,016,917 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 21:19 UTC |
PostFinance AG10% owner
|
SaleCommon Stock | 185,272 | $0.31 | $58,323.63 |
DisclosureSEC source: 0000899243-18-003865 · doc4.xml · nonDerivative · entry 1 PostFinance AG · CIK 0001727276 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,118,627 Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:07 UTC |
PostFinance AG10% owner
|
SaleCommon Stock | 7,552 | $0.34 | $2,567.68 |
DisclosureSEC source: 0000899243-18-003543 · doc4.xml · nonDerivative · entry 2 PostFinance AG · CIK 0001727276 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,303,899 Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:07 UTC |
PostFinance AG10% owner
|
SaleCommon Stock | 228,603 | $0.34 | $78,433.69 |
DisclosureSEC source: 0000899243-18-003543 · doc4.xml · nonDerivative · entry 1 PostFinance AG · CIK 0001727276 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,311,451 Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.34 | $6,800.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 10 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,328,229 Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 12,630 | $0.34 | $4,294.20 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 9 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,348,229 Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.34 | $6,812.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 8 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,360,859 Read SEC document |
| January 11, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.34 | $6,810.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 7 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,380,859 Read SEC document |
| January 10, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 15,796 | $0.38 | $6,007.22 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 6 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400,859 Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.39 | $7,804.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 5 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416,655 Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.40 | $7,928.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 4 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,436,655 Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.38 | $7,600.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 3 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,456,655 Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.38 | $7,600.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 2 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,476,655 Read SEC document |
| January 09, 2018 Filed Jan 11, 2018 17:08 UTC |
Swissquote Bank SA10% owner
|
SaleCommon Stock | 20,000 | $0.37 | $7,400.00 |
DisclosureSEC source: 0001140361-18-001693 · form4.xml · nonDerivative · entry 1 Swissquote Bank SA · CIK 0001727463 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,496,655 Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:40 UTC |
RICKEY DAVIDDirector
|
OtherWarrants (Right to Buy) · Derivative | 10,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062903 · doc4.xml · derivative · entry 3 RICKEY DAVID · CIK 0001184566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:40 UTC |
RICKEY DAVIDDirector
|
OtherSeries B Preferred Stock · Derivative | 6 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062903 · doc4.xml · derivative · entry 2 RICKEY DAVID · CIK 0001184566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Common Stock · 18,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:40 UTC |
RICKEY DAVIDDirector
|
OtherSubscription Rights (Right to Buy) · Derivative | 6 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062903 · doc4.xml · derivative · entry 1 RICKEY DAVID · CIK 0001184566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC |
Naughton Gail KDirector
|
OtherWarrants (Right to Buy) · Derivative | 1,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 3 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC |
Naughton Gail KDirector
|
OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 2 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:39 UTC |
Naughton Gail KDirector
|
OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062901 · doc4.xml · derivative · entry 1 Naughton Gail K · CIK 0001297506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:35 UTC |
Hawkins Richard JDirector
|
OtherWarrants (Right to Buy) · Derivative | 5,400 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062898 · doc4.xml · derivative · entry 3 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:35 UTC |
Hawkins Richard JDirector
|
OtherSeries B Preferred Stock · Derivative | 3 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062898 · doc4.xml · derivative · entry 2 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:35 UTC |
Hawkins Richard JDirector
|
OtherSubscription Rights (Right to Buy) · Derivative | 3 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062898 · doc4.xml · derivative · entry 1 Hawkins Richard J · CIK 0001307632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:36 UTC |
HEDRICK MARC HDirector · President and CEO
|
OtherWarrants (Right to Buy) · Derivative | 16,200 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062899 · doc4.xml · derivative · entry 3 HEDRICK MARC H · CIK 0001203672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:36 UTC |
HEDRICK MARC HDirector · President and CEO
|
OtherSeries B Preferred Stock · Derivative | 9 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062899 · doc4.xml · derivative · entry 2 HEDRICK MARC H · CIK 0001203672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9 Underlying: Common Stock · 27,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:36 UTC |
HEDRICK MARC HDirector · President and CEO
|
OtherSubscription Rights (Right to Buy) · Derivative | 9 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062899 · doc4.xml · derivative · entry 1 HEDRICK MARC H · CIK 0001203672 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:33 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherWarrants (Right to Buy) · Derivative | 1,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062896 · doc4.xml · derivative · entry 3 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:33 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062896 · doc4.xml · derivative · entry 2 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:33 UTC |
Girao TiagoVP & Chief Financial Officer
|
OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062896 · doc4.xml · derivative · entry 1 Girao Tiago · CIK 0001618670 · VP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:34 UTC |
HARRIS JOHN DAVIDVP and GM Cell Therapy
|
OtherWarrants (Right to Buy) · Derivative | 1,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062897 · doc4.xml · derivative · entry 3 HARRIS JOHN DAVID · CIK 0001655866 · VP and GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:34 UTC |
HARRIS JOHN DAVIDVP and GM Cell Therapy
|
OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-17-062897 · doc4.xml · derivative · entry 2 HARRIS JOHN DAVID · CIK 0001655866 · VP and GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:34 UTC |
HARRIS JOHN DAVIDVP and GM Cell Therapy
|
OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-17-062897 · doc4.xml · derivative · entry 1 HARRIS JOHN DAVID · CIK 0001655866 · VP and GM Cell Therapy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| November 28, 2017 Filed Feb 9, 2018 21:54 UTC |
LYONS GARY ADirector
|
OtherWarrants (Right to Buy) · Derivative | 1,800 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-18-008901 · doc4.xml · derivative · entry 3 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires 2020-05-28 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3 · derivative.exercise_date: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. Read SEC document |
| November 28, 2017 Filed Feb 9, 2018 21:54 UTC |
LYONS GARY ADirector
|
OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-18-008901 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Feb 9, 2018 21:54 UTC |
LYONS GARY ADirector
|
OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-008901 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:35 UTC |
LAPOINTE ANTHONY GREGGDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-17-034968 · doc4.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-03-31 F1 · derivative.exercise_price: The option grant was approved by the issuer's board of directors on March 31, 2017, subject to stockholder approval of the amendment and restatement of the issuer's 2014 Equity Incentive Plan (the "Restated Plan") under which the option was granted. The issuer's stockholders approved the Restated Plan on May 22, 2017. F2 · derivative.exercise_date: Fifty percent (50%) of the option shares shall vest on March 31, 2018 with the remaining fifty percent (50%) of the option shares vesting on March 31, 2019. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 22:58 UTC |
Marino MarkChief Medical Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-17-019945 · doc4.xml · derivative · entry 1 Marino Mark · CIK 0001681754 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the option shares shall vest and become exercisable on March 8, 2018 with the remaining option shares vesting and becoming exercisable in thirty-six (36) consecutive monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.